Michael J. Brooks is President at Edesa Biotech, Inc. (EDSA). They have made 10 open-market trades across 1 company since 2020, most recently 2026-05-27.
CIK 0001779126
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $77K since 2020, never a sale. Across 10 scored buys the stock is down 6.2% at ninety days, and 8.9 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| EDSA | 291,479 | $742K |
Shares reported on the most recent Form 4, priced at the 2026-05-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 90% | 50% | 40% |
| Avg Move | +9.1% | +2.6% | -6.2% |
| Alpha | +6.0% | -1.3% | -8.9% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EDSA | BUY | 2026-02-26 | 2026-03-11 | $1.57 | $3K | +18.1% | -16.2% | -28.5% |
| EDSA | BUY | 2022-06-29 | 2022-06-30 | $1.49 | $4K | +14.6% | +8.2% | -12.0% |
| EDSA | BUY | 2022-06-16 | 2022-06-21 | $1.61 | $5K | -3.6% | +4.2% | +0.0% |
| EDSA | BUY | 2022-05-25 | 2022-05-26 | $1.74 | $6K | +8.2% | -15.2% | +1.6% |
| EDSA | BUY | 2022-03-14 | 2022-03-15 | $2.79 | $3K | +3.5% | -8.7% | -44.8% |
| EDSA | BUY | 2022-03-10 | 2022-03-11 | $3.22 | $3K | +12.1% | -6.1% | -33.7% |
| EDSA | BUY | 2022-03-08 | 2022-03-09 | $2.90 | $4K | +20.4% | -16.7% | -39.0% |
| EDSA | BUY | 2021-03-25 | 2021-03-26 | $5.19 | $18K | +8.4% | +11.1% | +5.0% |
| EDSA | BUY | 2021-03-24 | 2021-03-25 | $5.08 | $23K | +7.1% | +10.9% | +3.4% |
| EDSA | BUY | 2020-05-27 | 2020-05-29 | $3.00 | $8K | +2.3% | +54.8% | +85.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.